"We are continuing to develop a portfolio of uniquely positioned medical devices employing our platform technology and expertise in the growing field of temperature modulation therapy," added Reinhard. "These new products, like UroCool, are being developed for specific and defined vertical market opportunities for companies having established sales and marketing organizations, and we plan to structure these vertical market opportunities through strategic alignments, financings and other transactions in keeping with our ongoing strategy to leverage and monetize Cardium's InnerCool investment."
According to the American Cancer Society, prostate cancer is the most
common cancer in American men other than skin cancers. One in six men will
develop prostate cancer in their lifetime, and in 2007 over 200,000 men
were newly diagnosed with the disease. Fortunately, prostate cancer grows
relatively slowly and 7 out of 10 men are diagnosed in the early stages of
the disease before it has spread to other parts of their body, thus leading
to significantly increased survival with proper treatment. While the
underlying cause for the development of prostate cancer is still unknown,
factors such as age, race, and lifestyle affect the probability of
developing the disease. Of these, age is the strongest risk factor, and as
life spans continue to increase, more men are surviving to an age at which
prostate cancer is more prevalent. The chances of developing prostate
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved